These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 20933468)

  • 21. Functional selectivity of GPCR ligand stereoisomers: new pharmacological opportunities.
    Seifert R; Dove S
    Mol Pharmacol; 2009 Jan; 75(1):13-8. PubMed ID: 19001067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeling G protein-coupled receptors in complex with biased agonists.
    Costanzi S
    Trends Pharmacol Sci; 2014 Jun; 35(6):277-83. PubMed ID: 24793542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of the ghrelin receptor is described by a privileged collective motion: a model for constitutive and agonist-induced activation of a sub-class A G-protein coupled receptor (GPCR).
    Floquet N; M'Kadmi C; Perahia D; Gagne D; Bergé G; Marie J; Banères JL; Galleyrand JC; Fehrentz JA; Martinez J
    J Mol Biol; 2010 Jan; 395(4):769-84. PubMed ID: 19782690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional selectivity of G-protein-coupled receptors: from recombinant systems to native human cells.
    Seifert R
    Biochem Pharmacol; 2013 Oct; 86(7):853-61. PubMed ID: 23933388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular basis of inverse agonism in a G protein-coupled receptor.
    Vilardaga JP; Steinmeyer R; Harms GS; Lohse MJ
    Nat Chem Biol; 2005 Jun; 1(1):25-8. PubMed ID: 16407989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulating G-protein-coupled receptors: from traditional pharmacology to allosterics.
    Gilchrist A
    Trends Pharmacol Sci; 2007 Aug; 28(8):431-7. PubMed ID: 17644194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation.
    Hoare SR; Fleck BA; Gross RS; Crowe PD; Williams JP; Grigoriadis DE
    Mol Pharmacol; 2008 May; 73(5):1371-80. PubMed ID: 18239030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural insights into agonist-induced activation of G-protein-coupled receptors.
    Deupi X; Standfuss J
    Curr Opin Struct Biol; 2011 Aug; 21(4):541-51. PubMed ID: 21723721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [G-protein-coupled receptors plasticity and signalling].
    Galés C
    Med Sci (Paris); 2012 Oct; 28(10):883-5. PubMed ID: 23067421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Refining efficacy: exploiting functional selectivity for drug discovery.
    Gesty-Palmer D; Luttrell LM
    Adv Pharmacol; 2011; 62():79-107. PubMed ID: 21907907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function.
    Kristiansen K
    Pharmacol Ther; 2004 Jul; 103(1):21-80. PubMed ID: 15251227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying Functional Hotspot Residues for Biased Ligand Design in G-Protein-Coupled Receptors.
    Nivedha AK; Tautermann CS; Bhattacharya S; Lee S; Casarosa P; Kollak I; Kiechle T; Vaidehi N
    Mol Pharmacol; 2018 Apr; 93(4):288-296. PubMed ID: 29367258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LITiCon: a discrete conformational sampling computational method for mapping various functionally selective conformational states of transmembrane helical proteins.
    Bhattacharya S; Vaidehi N
    Methods Mol Biol; 2012; 914():167-78. PubMed ID: 22976028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha2C-adrenergic receptors exhibit enhanced surface expression and signaling upon association with beta2-adrenergic receptors.
    Prinster SC; Holmqvist TG; Hall RA
    J Pharmacol Exp Ther; 2006 Sep; 318(3):974-81. PubMed ID: 16757535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of the A2A adenosine G-protein-coupled receptor by conformational selection.
    Ye L; Van Eps N; Zimmer M; Ernst OP; Prosser RS
    Nature; 2016 May; 533(7602):265-8. PubMed ID: 27144352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective.
    Shonberg J; Lopez L; Scammells PJ; Christopoulos A; Capuano B; Lane JR
    Med Res Rev; 2014 Nov; 34(6):1286-330. PubMed ID: 24796277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Agonist binding: a multistep process.
    Kobilka B
    Mol Pharmacol; 2004 May; 65(5):1060-2. PubMed ID: 15102933
    [No Abstract]   [Full Text] [Related]  

  • 38. Dynamics and flexibility of G-protein-coupled receptor conformations and their relevance to drug design.
    Vaidehi N
    Drug Discov Today; 2010 Nov; 15(21-22):951-7. PubMed ID: 20831898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. G protein-coupled receptors: a count of 1001 conformations.
    Vauquelin G; Van Liefde I
    Fundam Clin Pharmacol; 2005 Feb; 19(1):45-56. PubMed ID: 15660959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How ligands and signalling proteins affect G-protein-coupled receptors' conformational landscape.
    Mary S; Fehrentz JA; Damian M; Verdié P; Martinez J; Marie J; Banères JL
    Biochem Soc Trans; 2013 Feb; 41(1):144-7. PubMed ID: 23356274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.